Lineage Cell Therapeutics, Inc.LCTXNYSE
Loading
Operating cash flow minus capital expenditures
Percentile
P86
Within normal range
vs 3Y Ago
-30.1x
Contraction
Streak
2 yr
Consecutive growthExpanding
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $-19.44M | +17.8% |
| 2024 | $-23.66M | +19.1% |
| 2023 | $-29.24M | -4626.3% |
| 2022 | $646000.00 | +102.7% |
| 2021 | $-23.91M | -20.7% |
| 2020 | $-19.82M | +38.8% |
| 2019 | $-32.39M | +5.2% |
| 2018 | $-34.17M | -7.3% |
| 2017 | $-31.84M | +29.0% |
| 2016 | $-44.85M | - |